No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
EBS250117C10000
- 0.12
- +0.02+20.00%
15min DelayClose Jan 14 16:00 ET
0.26High0.10Low
0.26Open0.10Pre Close55 Volume919 Open Interest10.00Strike Price760.00Turnover98.82%IV8.12%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.2286Delta0.3856Gamma93.60Leverage Ratio-0.0468Theta0.0001Rho21.40Eff Leverage0.0024Vega
Intraday
- 5D
- Daily
News
Express News | Emergent BioSolutions Shares up 4.3% on Gaining Commercial Rights for Hikma's Opioid Overdose Treatment
Express News | Emergent BioSolutions Gains Exclusive Commercial Rights to Kloxxado® (Naloxone Hci) Nasal Spray From Hikma Pharmaceuticals
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO (Naloxone HCI) Nasal Spray From Hikma Pharmaceuticals
Emergent BioSolutions Receives $16.7M Contract Option To Continue Development Collaboration With BARDA On Ebanga Treatment For Ebola
Express News | Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration With Barda on Ebanga™ (Ansuvimab-Zykl) Treatment for Ebola
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration With BARDA on Ebanga (Ansuvimab-zykl) Treatment for Ebola